116 related articles for article (PubMed ID: 38186024)
1. SIGNIFICANCE OF OSTEOPONTIN FOR PREDICTING AGGRESSIVENESS OF PROSTATE CANCER.
Lukianova N; Zadvornyi Т; Borikun Т; Mushii О; Pavlova А; Tymoshenko А; Stakhovskyi Е; Vitruk I; Сhekhun V
Exp Oncol; 2023 Dec; 45(3):312-321. PubMed ID: 38186024
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
3. [Expression of osteopontin splice variant and its clinical significance in gastric cancer].
Sun X; Wang L; Hou W; Li Y; Liu L; Zuo W; Yu J
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):427-30. PubMed ID: 26463145
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological and prognostic significance of osteopontin expression in patients with prostate cancer: a systematic review and meta-analysis.
Yu A; Guo K; Qin Q; Xing C; Zu X
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 33635319
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of osteopontin expression in human gastric carcinoma.
Higashiyama M; Ito T; Tanaka E; Shimada Y
Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
[TBL] [Abstract][Full Text] [Related]
7. [Expression of osteopontin and survivin in prostate cancer and the clinical significance].
Yu HB; Han XB; Liang YQ; Liu JG; Wang H
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1141-3. PubMed ID: 20501415
[TBL] [Abstract][Full Text] [Related]
8. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
[TBL] [Abstract][Full Text] [Related]
9. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
[TBL] [Abstract][Full Text] [Related]
10. Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V; Borikun T; Zadvornyi T; Mushii O; Stakhovsky E; Vitruk Y; Lukianova N
Pathol Res Pract; 2024 Feb; 254():155053. PubMed ID: 38199134
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. [Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof].
Gui SY; Li HH; Zuo L; Zhou Q; Wu Q; Wang Y
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3219-23. PubMed ID: 18399118
[TBL] [Abstract][Full Text] [Related]
13. Dietary genistein improves survival and reduces expression of osteopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP).
Mentor-Marcel R; Lamartiniere CA; Eltoum IA; Greenberg NM; Elgavish A
J Nutr; 2005 May; 135(5):989-95. PubMed ID: 15867270
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
15. [Expression of osteopontin mRNA and its clinical significance in gastric cancer].
Sun XJ; Zuo WS; Ma H; Hou WH; Cai SP; Jiang XH
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):292-5. PubMed ID: 15996323
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of osteopontin and CD44v9 in gastric cancer.
Ue T; Yokozaki H; Kitadai Y; Yamamoto S; Yasui W; Ishikawa T; Tahara E
Int J Cancer; 1998 Apr; 79(2):127-32. PubMed ID: 9583725
[TBL] [Abstract][Full Text] [Related]
17. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
Thoms JW; Dal Pra A; Anborgh PH; Christensen E; Fleshner N; Menard C; Chadwick K; Milosevic M; Catton C; Pintilie M; Chambers AF; Bristow RG
Br J Cancer; 2012 Aug; 107(5):840-6. PubMed ID: 22871886
[TBL] [Abstract][Full Text] [Related]
18. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
20. Mast cells as a tumor microenvironment factor associated with the aggressiveness of prostate cancer.
Zadvornyi T; Lukianova N; Borikun T; Tymoshenko A; Mushii O; Voronina O; Vitruk I; Stakhovskyi E; Chekhun V
Neoplasma; 2022 Dec; 69(6):1490-1498. PubMed ID: 36591806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
